REPEAT/Zaxis International Announces Leonard P. Tannen as President and Chief Executive Officer.Business Editors REPEATING DUE TO GARBLE gar·ble tr.v. gar·bled, gar·bling, gar·bles 1. To mix up or distort to such an extent as to make misleading or incomprehensible: She garbled all the historical facts. 2. HUDSON, Ohio--(BUSINESS WIRE)--Jan. 15, 2002 Zaxis International (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ZAXS), a protein separation based Biotechnology Company, today announced the appointment of Leonard P. Tannen to the position of President and Chief Executive Officer on a permanent basis. In addition, Mr. Tannen has been appointed to the Board of Directors effective immediately. Mr. Tannen, who holds a Masters in Biochemical Engineering Biochemical engineering The application of engineering principles to conceive, design, develop, operate, or use processes and products based on biological and biochemical phenomena. from MIT MIT - Massachusetts Institute of Technology , has been a Marketing and Sales consultant to the Company since May of 2000 and has extensive management experience operating biotechnology, OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). pharmaceutical and consumer related business. In each of these positions he led a variety of performance improvements and growth projects. "Focus and strategic direction are vital ingredients in our quest to achieve continued growth and success within the biotechnology industry," said Mr. Tannen. "I am also pleased to join my fellow board members and look forward to working with the many world-class companies associated with this organization." The Board of Directors made the following statement: "Len's acceptance of this leadership position provides tremendous continuity to our ongoing process. We are also pleased that his background in growing profitable business opportunities along with his focus on profit improvement will provide great benefit for our company." Zaxis International is a leader in the formulation and manufacture of pre-cast polyacrylamide gels pol·y·a·cryl·a·mide gel n. A hydrated polymer consisting of a long chain of amide groups, used as a medium for substances that undergo gel electrophoresis. for protein separation and purification applications in Genomic, Proteomic and Life Science research and manufacturing markets. The Company's proprietary formulations and manufacturing techniques, combined with the use of disposable 100% glass cassettes, provides the highest resolution, separation and reproducibility commercially available today. Zaxis International provides both standard and custom OEM (Original Equipment Manufacturer) The rebranding of equipment and selling it. The term initially referred to the company that made the products (the "original" manufacturer), but eventually became widely used to refer to the organization that buys the products and pre-cast gels for resale by manufacturers and distributors of diagnostic kits, DNA sequencers and 2-Dimensional protein separation systems. In addition Zaxis International distributes its branded products to large end users such as Proteomics, Pharmaceutical and Biotechnology organizations who require gel documentation and reproducible product performance. Zaxis recently announced the availability of a large format all glass 2D gel for use with Amersham Bioscience's Ettan DALT DALT Declarative Agent Languages and Technologies DALT Department of the Army Liaison Team DALT Distributed Artificial Life Toolkit DALT District Achievement Level Tests DALT Danish Autolog Team DALT Drop Altitude II System, a major component of the rapidly expanding Proteomics research market today. For more information about Zaxis International Inc. and its products, please visit our website at www.zaxis-inc.com or call us at 877.246.8665. This press release contains forward-looking statements within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements are subject to risks, uncertainties and other factors, which may cause the Company's results to differ materially from expectations. These risks and uncertainties include, but are not limited to, certain market risks, the ability of Zaxis International to develop and commercialize the products that are subject to this program and other risks and uncertainties in the Company's Securities and Exchange filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion